Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

More than an emotional support PET

Jens Hillengass

Blood (2025) 146 (25): 3006–3008.

https://doi.org/10.1182/blood.2025031179

Published: 2025

Journal Articles

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, JeeEun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund, Megan Schaefer, Hamza Hassan, Sarah Parker, Kenneth C. Anderson, Nikhil C. Munshi, Mehmet Samur, Philip L. McCarthy, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (20): 2392–2405.

https://doi.org/10.1182/blood.2025028963

Published: 2025

Includes: Supplemental data

Journal Articles

Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment

Muhammad Salman Faisal, Nour Nassour, Sean Glenn, Han Yu, Sarah Parker, Hamza Hassan, Jens Hillengass

Blood (2025) 146 (Supplement 1): 7484.

https://doi.org/10.1182/blood-2025-7484

Published: 2025

Journal Articles

Genomic determinants and differences of primary and secondary plasma cell leukemia

Mehmet Samur, Hamza Hassan, Qi Yan, Sarah Parker, Prashant Singh, Megan Schaefer, Kristina Slemmer, Kimberly Celotto, Ian Lund, Hailey Battaglia, Annmarie Nowak, Linda Lutgen, Saeed Daneshmandi, Kenan Onel, Philip McCarthy, Nikhil Munshi, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (Supplement 1): 7469.

https://doi.org/10.1182/blood-2025-7469

Published: 2025

Journal Articles

Peripheral blood immune profiling in newly diagnosed multiple myeloma: Associations with MRD status and high-risk cytogenetics

Anuja Abhyankar, Janine Joseph, Nour Nassour, Jas Virk, Sarah Parker, Hemn Mohammadpour, Joseph Tario, Philip McCarthy, Jens Hillengass

Blood (2025) 146 (Supplement 1): 7464.

https://doi.org/10.1182/blood-2025-7464

Published: 2025

Journal Articles

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Blood (2025) 146 (Supplement 1): 2289.

https://doi.org/10.1182/blood-2025-2289

Published: 2025

Journal Articles

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Janine Joseph, Joseph Tario, Han Yu, Sarah Parker, Ian Lund, Kristina Slemmer, Hailey Battaglia, Megan Schaefer, Kimberly Celotto, Philip McCarthy, Hamza Hassan, Hemn Mohammadpour, Jens Hillengass

Blood (2025) 146 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2025-1411

Published: 2025

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

Circulating immune profile in patients with amyloidosis

Janine Joseph, Joseph Tario, Han Yu, Philip McCarthy, Hamza Hassan, Sarah Parker, Megan Schaefer, Hailey Battaglia, Hemn Mohammadpour, Jens Hillengass

Blood (2025) 146 (Supplement 1): 5748.

https://doi.org/10.1182/blood-2025-5748

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025

Journal Articles

Impact of pre-transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation

Sawyer Bawek, Matthew Burwinkel, Nisha Nair, Lacey Yuan, Hillary Jacobson, Han Yu, Theresa Hahn, Jens Hillengass, Megan Herr

Blood (2025) 146 (Supplement 1): 5798.

https://doi.org/10.1182/blood-2025-5798

Published: 2025

Journal Articles

Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis

Zunairah Shah, Ian Lund, Sarah Parker, Kimberly Celotto, Kristina Slemmer, Hailey Battaglia, Megan Schaefer, Yongdong Ouyang, Hamza Hassan, Jens Hillengass

Blood (2025) 146 (Supplement 1): 7532.

https://doi.org/10.1182/blood-2025-7532

Published: 2025

Journal Articles

Differences in Immune Cell Populations between Individuals with or without MGUS

Sawyer Bawek, Janine M. Joseph, Alan Hutson, Sarah Parker, Joseph D. Tario Jr, Hamza Hassan, Scott I. Abrams, Jens Hillengass

Blood (2024) 144 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2024-206171

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Esraa Abdalla, Malak Alharbi, Sawyer Bawek, Catherine Forbes, Ian Lund, Han Yu, Berthliz Durand, Jens Hillengass, Hamza Hassan, Eugene Przespolewski

Blood (2024) 144 (Supplement 1): 5158.

https://doi.org/10.1182/blood-2024-206022

Published: 2024

Journal Articles

MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study

Marina Hajiyianni, Christos Sachpekidis, Annette Kopp-Schneider, Elias Karl Mai, Sandra Sauer, Ekaterina Menis, Michael Hundemer, Niels Weinhold, Jens Hillengass, Marc-Steffen Raab, Antonia Dimitrakopoulou-Strauss, Hartmut Goldschmidt

Blood (2024) 144 (Supplement 1): 4701.

https://doi.org/10.1182/blood-2024-210171

Published: 2024

Journal Articles

Clinical Characteristics and Survival Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia According to the 2021 Definition: A Single Center Retrospective Study

Khalid Shalaby, Farhan Azad, Sarah Parker, Katy Wang, Kristopher Attwood, Jens Hillengass

Blood (2024) 144 (Supplement 1): 6960.

https://doi.org/10.1182/blood-2024-198790

Published: 2024

Journal Articles

Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients

Janine M. Joseph, Michaela Hillengass, Bryan J. Wittmeyer, Carolyn A. Miller, Hillary M. Jacobson, Kirsten B. Moysich, Rikki A. Cannioto, Jens Hillengass

Blood (2024) 144 (Supplement 1): 705.

https://doi.org/10.1182/blood-2024-211391

Published: 2024

Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2023-182345

Published: 2023

Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Blood (2023) 142 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2023-186997

Published: 2023

Journal Articles

Effects of Dose Reductions of Lenalidomide Given As Maintenance Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Ian Lund, Farhan Azad, Kristopher Attwood, Anthony George, Jens Hillengass

Blood (2023) 142 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2023-181708

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

More than an emotional support PET

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment

Genomic determinants and differences of primary and secondary plasma cell leukemia

Peripheral blood immune profiling in newly diagnosed multiple myeloma: Associations with MRD status and high-risk cytogenetics

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Circulating immune profile in patients with amyloidosis

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Impact of pre-transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation

Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis

Differences in Immune Cell Populations between Individuals with or without MGUS

Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study

Clinical Characteristics and Survival Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia According to the 2021 Definition: A Single Center Retrospective Study

Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Effects of Dose Reductions of Lenalidomide Given As Maintenance Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only